Skip to main content
. 2020 Jan 20;2020(1):CD011628. doi: 10.1002/14651858.CD011628.pub2

Comparison 10. Guselkumab 200 mg vs placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Proportion of participants cleared or almost cleared in the short term 2 154 Risk Ratio (M‐H, Random, 95% CI) 1.17 [0.15, 9.30]
2 Proportion of participants with adverse effects serious or severe enough to have caused withdrawal of participants from the study 1 49 Risk Ratio (M‐H, Random, 95% CI) 2.88 [0.32, 25.80]
3 Proportion of participants achieving a 50% reduction in disease severity 1 49 Risk Ratio (M‐H, Random, 95% CI) 2.88 [1.24, 6.69]